Home » Stocks » KRTX

Karuna Therapeutics, Inc. (KRTX)

Stock Price: $113.31 USD -4.53 (-3.84%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $115.01 +1.70 (1.50%) Jul 23, 6:25 PM
Market Cap 3.34B
Revenue (ttm) n/a
Net Income (ttm) -90.39M
Shares Out 29.46M
EPS (ttm) -3.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $113.31
Previous Close $117.84
Change ($) -4.53
Change (%) -3.84%
Day's Open 118.17
Day's Range 111.41 - 118.17
Day's Volume 160,265
52-Week Range 69.58 - 146.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced the pricing of an underwritten public offering.

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...

Other stocks mentioned: PRTC
5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX #NEJM--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

8 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

8 months ago - Business Wire

It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.

Other stocks mentioned: APPS, BE, EXPI, INO, OSTK, VSLR
9 months ago - InvestorPlace

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform...

10 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

11 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

11 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

11 months ago - Business Wire

BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc.

11 months ago - Business Wire

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...

1 year ago - Business Wire

Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

1 year ago - Zacks Investment Research

Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.

Other stocks mentioned: LVGO, PFSI, SFM, STRA
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).

1 year ago - Zacks Investment Research

COVID-19 and initial public offerings don’t go well together.

Other stocks mentioned: BYND, FB, LYFT, UBER
1 year ago - The Motley Fool

The volatile biotech has been up and down since its massive gain back in November.

1 year ago - The Motley Fool

The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.

1 year ago - The Motley Fool

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who ...

Other stocks mentioned: BYND, CRTX, IGMS, INMD, NXTC, PLMR, SWAV ...
1 year ago - ETF Trends

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, APRE, BNTX, GKOS, INMD, NXTC, PLMR ...
1 year ago - The Motley Fool

This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

Other stocks mentioned: BYND, SILK, TPTX, ZM
1 year ago - Zacks Investment Research

An index that tracks initial public offerings has outperformed the S&P 500 in what could be a historic year for stocks.

Other stocks mentioned: BYND, CHWY
1 year ago - CNBC

Is the stock a buy now that the price has dropped?

1 year ago - The Motley Fool

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?

Other stocks mentioned: AXSM, KOD
1 year ago - The Motley Fool

In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.

1 year ago - InvestorPlace

4 Biotech Neurology Stocks, As Biotechs March On

Other stocks mentioned: ACAD, NBIX, NERV
1 year ago - Seeking Alpha

Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock.

1 year ago - InvestorPlace

As of late, it has definitely been a great time to be an investor Karuna Therapeutics

1 year ago - Zacks Investment Research

Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia Study

1 year ago - Seeking Alpha

Karuna Therapeutics Tests Our Theories!

1 year ago - The Motley Fool

Karuna Therapeutics: Fundraising Makes For Buying Opportunity

1 year ago - Seeking Alpha

"We're cautiously optimistic given the robustness of the clinical data that we reported this week," Karuna Therapeutics CEO Dr. Steve Paul says.

1 year ago - CNBC

Karuna Therapeutics soars on potentially 'game changing' new schizophrenia drug

YouTube video

Karuna CEO Dr.

1 year ago - CNBC Television

History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.

1 year ago - The Motley Fool

The pharma company announced the pricing of a public stock offering.

1 year ago - The Motley Fool

Positive clinical trial results recently sent this stock soaring, but can it climb further?

1 year ago - The Motley Fool

About KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the t... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2019
Stock Exchange
NASDAQ
Ticker Symbol
KRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for KRTX stock is "Strong Buy." The 12-month stock price forecast is 160.31, which is an increase of 41.48% from the latest price.

Price Target
$160.31
(41.48% upside)
Analyst Consensus: Strong Buy